1340P Propensity Score Matching Analysis for Osimertinib Versus Comparator First-Generation EGFR Tyrosine Kinase Inhibitors As First-Line Treatment in Patients with Advanced EGFR-mutated Non–small Cell Lung Cancer: A Chinese, Multicenter, Real-World Cohort Study

D. Zhang, X. Liu,F. Shen, D. Zhao, Y. Shi, H. Zhang,J. Liu, X. Gao,M. Chen, J. Zhao,W. Zhong, Y. Xu, M. Wang

Annals of Oncology（2023）

Cited 0|Views7

No score

Key words

Osimertinib,comparator epidermal growth factor receptor tyrosine kinase inhibitor (comparator EGFR-TKI),propensity score matching (PSM),real-world study

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined